Related Experiment Video

Updated: May 22, 2026

Biochemical Measurement of Neonatal Hypoxia
13:13

Biochemical Measurement of Neonatal Hypoxia

Published on: August 24, 2011

UGT1A1, SLCO1B1, and SLCO1B3 polymorphisms vs. neonatal hyperbilirubinemia: is there an association?

Laura Alencastro de Azevedo1, Themis Reverbel da Silveira, Clarissa Gutierrez Carvalho

  • 1Postgraduate Program in Child and Adolescent Health, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

Pediatric Research
|May 15, 2012
PubMed

Insights

Genetic variations in newborns can influence jaundice risk, especially with other conditions. Certain gene variants may offer protection against hyperbilirubinemia, while others combined with G6PD deficiency increase risk.

Area of Science:

  • Neonatal Medicine
  • Medical Genetics
  • Pharmacogenomics

Background:

  • Jaundice is common in newborns, but severe hyperbilirubinemia affects 5-6%.
  • Genetic variations may increase hyperbilirubinemia risk when combined with other factors.
  • Investigating genetic predispositions is crucial for understanding severe neonatal jaundice.

Purpose of the Study:

  • To investigate the association between specific gene polymorphisms and the risk of severe hyperbilirubinemia in newborns.
  • To explore the role of UGT1A1, SLCO1B1, and SLCO1B3 gene variants in neonatal jaundice.

Main Methods:

  • Study included newborns with gestational age >35 weeks and weight >2,000g requiring phototherapy.
  • Analyzed polymorphisms in UGT1A1 (rs8175347), SLCO1B1 (rs4149056, rs2306283), and SLCO1B3 (rs17680137, rs2117032) using capillary electrophoresis.
  • Compared allelic and genotypic frequencies between 167 hyperbilirubinemic infants and 247 controls.

Main Results:

  • While gender, ABO incompatibility, birth weight, and gestational age differed, SLCO1B gene polymorphism frequencies did not significantly vary between groups.
  • Logistic regression identified ABO incompatibility, gestational age, and the rs2117032 T allele as significant factors.
  • The rs2117032 polymorphism appeared protective against hyperbilirubinemia.
  • Homozygosity for the rs2306283 G allele and glucose-6-phosphate-dehydrogenase deficiency were more common in infants with hyperbilirubinemia.

Conclusions:

  • Genetic variations contribute significantly to neonatal hyperbilirubinemia.
  • The interplay between genetic polymorphisms and environmental factors requires further investigation.
  • Understanding these associations can inform risk assessment and management strategies for neonatal jaundice.
Abstract

More Related Videos

Functional Characterization of Na+/H+ Exchangers of Intracellular Compartments Using Proton-killing Selection to Express Them at the Plasma Membrane07:38

Functional Characterization of Na+/H+ Exchangers of Intracellular Compartments Using Proton-killing Selection to Express Them at the Plasma Membrane

Published on: March 30, 2015

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...